Stockhub

CTI BioPharma Corp.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 August 2022

4 August 2022

  • curprev 22:1422:14, 4 August 2022‎ Paris talk contribs‎ 684 bytes +684‎ Created page with "CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxa..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/CTI_BioPharma_Corp.’